Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy

Experimental Neurology

Volumn 227, Issue 1, 2011, Pages 120-127

  Park, Susanna B ^a,b   Lin, Cindy S Y ^c   Krishnan, Arun V ^c   Goldstein, David ^d   Friedlander, Michael L ^d   Kiernan, Matthew C ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Membrane potential; Na+ channel; Natural activity; Nerve excitability; Oxaliplatin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); OXALIPLATIN; SODIUM CHANNEL;

ACUTE TOXICITY; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG INFUSION; ENZYME ACTIVITY; FEMALE; HAND MUSCLE; HUMAN; HYPERPOLARIZATION; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CONTRACTION; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CONDUCTION; NERVE EXCITABILITY; NERVOUS SYSTEM PARAMETERS; NEUROPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFRACTORY PERIOD; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; NEURAL CONDUCTION; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS;

EID: 78650925060     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.10.002     Document Type: Article

References (55)

1. Adelsberger H.S., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 2000, 406:25-32.
2. André T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J. Med. 2004, 350:2343-2351.
3. Baker M., Bostock H., Grafe P., Martius P. Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J. Physiol. 1987, 383:45-67.
4. Barrett E.F., Barrett J.N. Intracellular recording from vertebrate myelinated axons: mechanism of the depolarizing afterpotential. J. Physiol. 1982, 323:117-144.
5. + channels in frog peripheral myelinated axons. Gen. Physiol. Biophys. 2006, 25:263-276.
6. Bergmans J. Active and passive mechanisms in the recovery of single human motor axons from activity. Arch. Int. Physiol. Biochim. 1968, 76:135-138.
7. Bostock H., Grafe P. Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J. Physiol. 1985, 365:239-257.
8. Bostock H., Rothwell J.C. Latent addition in motor and sensory fibres of human peripheral nerve. J. Physiol. 1997, 498:277-294.
9. Bostock H., Cikurel K., Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998, 21:137-158.
10. Cappelen-Smith C., Kuwabara S., Lin C.S.-Y., Mogyoros I., Burke D. Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. 2000, 48:826-832.
11. Cassidy J., Misset J.L. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 2002, 29:11-20.
12. Cassidy J., Tabernero J., Twelves C., Brunet R., Butts C., Conroy T., Debraud F., Figer A., Grossmann J., Sawada N., Schoffski P., Sobrero A., Van Cutsem E., Diaz-Rubio E. Xelox (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 2004, 22:2084-2091.
13. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18:2938-2947.
14. Gamelin E., Gamelin L., Bossi L., Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. 2002, 29:21-33.
15. Gasser H.S. Changes in nerve-potentials produced by rapidly repeated stimuli and their relation to the responsiveness of nerve to stimulation. Am. J. Physiol. 1935, 111:35-50.
16. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 2001, 85:2293-2297.
17. Grosskreutz J., Lin C.S.-Y., Mogyoros I., Burke D. Ischaemic changes in refractoriness of human cutaneous afferents under threshold-clamp conditions. J. Physiol. 2000, 523:807-815.
18. Hodgkin A.L., Huxley A.F. A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol. 1952, 117:500-544.
19. Kaji R., Bostock H., Kohara N., Murase N., Kimura J., Shibasaki H. Activity-dependent conduction block in multifocal motor neuropathy. Brain 2000, 123:1602-1611.
20. Kiernan M.C., Mogyoros I., Burke D. Differences in the recovery of excitability in sensory and motor axons of human median nerve. Brain 1996, 119:1099-1105.
21. Kiernan M.C., Mogyoros I., Hales J.P., Gracies J.M., Burke D. Excitability changes in human cutaneous afferent induced by prolonged repetitive axonal activity. J. Physiol. 1997, 500:255-264.
22. Kiernan M.C., Burke D., Andersen K.V., Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000, 23:399-409.
23. Kiernan M.C., Lin C.S.-Y., Burke D. Differences in activity-dependent hyperpolarization in human sensory and motor axons. J. Physiol. 2004, 558:341-349.
24. Kiernan M.C., Isbister G.K., Lin C.S.-Y., Burke D., Bostock H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann. Neurol. 2005, 57:339-348.
25. Kiernan M.C., Krishnan A.V. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr. Med. Chem. 2006, 13:2901-2907.
26. Krishnan A.V., Goldstein D., Friedlander M., Kiernan M.C. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51-60.
27. Krishnan A.V., Kiernan M.C. Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve 2006, 33:627-636.
28. + channel function in vivo. Clin. Cancer Res. 2006, 12:4481-4484.
29. + pump function and activity-dependent excitability changes in end-stage kidney disease. Clin. Neurophysiol. 2006, 117:992-999.
30. + pump dysfunction in diabetic neuropathy. Brain 2008, 131:1209-1216.
31. Krishnan A.V., Lin C.S.-Y., Reddel S.W., McGrath R., Kiernan M.C. Conduction block and impaired axonal function in tick paralysis. Muscle Nerve 2009, 40:358-362.
32. Krishnan A.V., Lin C.S.-Y., Park S.B., Kiernan M.C. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog. Neurobiol. 2009, 89:288-313.
33. Kuwabara S., Lin C.S.-Y., Mogyoros I., Cappelen-Smith C., Burke D. Voluntary contraction impairs the refractory period of transmission in healthy human axons. J. Physiol. 2001, 531:265-275.
34. Kuwabara S., Cappelen-Smith C., Lin C.S.-Y., Mogyoros I., Burke D. Effects of voluntary activity on the excitability of motor axons in the peroneal nerve. Muscle Nerve 2002, 25:176-184.
35. Kuwabara S., Bostock H., Ogawara K., Sung J.Y., Kanai K., Mori M., Hattori T., Burke D. The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve 2003, 28:683-689.
36. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
37. Lin C.S.-Y., Mogyoros I., Burke D. Recovery of excitability of cutaneous afferents in the median and sural nerves following activity. Muscle Nerve 2000, 23:763-770.
38. Maindrault-Goebel F., Louvet C., André T., Carola E., Lotz J.P., Molitor J.L., Garcia M.L., Gilles-Amar V., Izrael V., Krulik M., de Gramont A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur. J. Cancer 1999, 35:1338-1342.
39. Mogyoros I., Kiernan M.C., Burke D. Strength-duration properties of human peripheral nerve. Brain 1996, 119:439-447.
40. + pump in lizard axons impaled near their motor terminals. J. Neurophysiol. 1993, 70:1874-1884.
41. Olsson Y. Topographical differences in the vascular permeability of the peripheral nervous system. Acta Neuropathol. 1969, 10:26-33.
42. Park S.B., Krishnan A.V., Lin C.S.-Y., Goldstein D., Friedlander M., Kiernan M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem. 2008, 15:3081-3094.
43. Park S.B., Goldstein D., Lin C.S.-Y., Krishnan A.V., Friedlander M.L., Kiernan M.C. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J. Clin. Oncol. 2009, 27:1243-1249.
44. Park S.B., Lin C.S.-Y., Krishnan A.V., Goldstein D., Friedlander M.L., Kiernan M.C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009, 132:2712-2723.
45. Rakowski R.F., Gadsby D.C., De Weer P. Stoichiometry and voltage dependence of the sodium pump in voltage-clamped internally dialyzed squid giant axon. J. Gen. Physiol. 1989, 93:903-941.
46. Schwarz J.R., Reid G., Bostock H. Action potential and membrane currents in the human node of Ranvier. Pflügers Arch. 1995, 430:283-292.
47. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., Langer C., Murphy B., Cumberlin R., Coleman C.N., Rubin P.C. CTCAE V3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003, 13:176-181.
48. Ulbricht W. Sodium channel inactivation: molecular determinants and modulation. Physiol. Rev. 2005, 85:1271-1301.
49. Vagg R., Mogyoros I., Kiernan M.C., Burke D. Activity-dependent hyperpolarization of human motor axons produced by natural activity. J. Physiol. 1998, 507:919-925.
50. Vucic S., Krishnan A.V., Kiernan M.C. Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2007, 78:1202-1208.
51. Webster R.G., Brain K.L., Wilson R.H., Grem J.L., Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 2005, 146:1027-1039.
52. Weiss G. Sur la possibilité de rendre comparables entre eux les appareils servant á l'excitation electrique. Arch. Ital. Biol. 1901, 35:413-446.
53. Westerfield M., Joyner R.W., Moore J.W. Temperature-sensitive conduction failure at axon branch points. J. Neurophysiol. 1978, 41:1-8.
54. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 2002, 20:1767-1774.
55. Wu S.N., Chen B.S., Wu Y.H., Peng H., Chen L.T. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated Ng108-15 neuronal cells. Neurotoxicology 2009, 30:677-685.